Vintage, Forough is actually the CTO, Konstanty is head of Tech Development. Stuart is also an employee of the company, hence the "Emeritus" title. I understand there is a link to UQ, but it is def less relevant these days as (like you mentioned above) EMV have built up a very talented internal team. Reducing the responsibility of external sources and building in house expertise has significantly reduced risk and no doubt improved efficiencies.
I am unsure of the IP position of certain UQ projects, if EMV thought there could be potential commercial possibilities moving forward I'm sure they would pursue them. Right now it seems we are solely focussed on Stroke and possibly TBI down the track.
Michael, I believe the changes will be minimal to EMV, possibly beneficial....time will tell.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)